Drägerwerk AG & Co KGaA

Resilient Orders Amidst Margin Pressures in Q2 2025

14/07/25 -"Drägerwerk’s Q2 2025 preliminary results fell short of our estimates. Net sales increased by 1.8%, with a 5% growth in the medical division counterbalancing a 2% decline in the safety division. ..."

PDF page sample
Pages
47
Language
English
Published on
14/07/25
Download
You may also be interested by these reports :
14/07/25
Drägerwerk’s Q2 2025 preliminary results fell short of our estimates. Net sales increased by 1.8%, with a 5% growth in the medical division ...
11/07/25
Given the numerous new product launches, high adoption of existing products, increased presence in point-of-care testing and robust balance sheet, we ...
07/07/25
Sartorius (BUY; Germany), a historically pristine business, has fallen off its perch. Following the big and expensive bet on Polyplus, Sartorius ...
04/07/25
We’ve updated our forecasts to reflect the latest asset disposals, including Baywater (expected to generate €60m revenue in FY24/25 ending June ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO